Original document(14 pages)  中文版
    The present invention relates to an erythrocyte duoparental depressor factor (EDDF), its preparation method and application. Its preparation method includes the following steps: using human blood and adopting centrifugal separation process to obtain erythrocyte, using deionized water to hemolyze erythrocyte, after the hemolysate is stood still at 4 deg.C, heating the hemolysate at water bath with 100 deg.C, then cooling in ice bath, centrifugalizing obtained product more than 12000g at 4 deg.C to take supernatant, ultrafiltering supernatant to collect the ultrafiltrate whose molecular weight is less than 500D, freeze-drying said ultrafiltrate, making the freeze-dried sample undergo the process of column chromatograph for sorting and separation so as to obtain the invented product which can be used for preparing medicine for curing hypertension disease.
Application Number
申请号
02106068 Application Date
申请日
2002.04.11
Title 名称 Human red blood cell source depressor factor and use thereof
Publication Number
公开号
1450085 Publication Date
公开日
2003.10.22
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K35/18,A61P9/12,C07K14/435
Applicant(s) Name
申请人
Inst. of Predinical Medicine CAS
Address 地址 100005
Inventor(s) Name 发明人
Attorney & Agent 代理人 lin xiaogong

  
Medical and health care use of adenyl and guanyl kind compound and medicine or health protection product for reducing blood pressure and improving cardio and vascular function
A kind of compound, its pharmaceutical composition and its medicinal and health uses
Anti SARS specificity IgY and combination preparation thereof
Recombinant Toxoplasma fusion protein antigen and preparation process and use thereof
Novel method for producing carragheen
Metallocene titanium compound and use thereof
Benzene free type fluorocarbon resin
Ultralow surface energy type fluorocarbon resin
Polymer particle stabilized by dispersant and method of preparation
Catalyst for preparing syndiotacti polystyrene
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.